In vitro circuit stability of 5-fluorouracil and oxaliplatin in support of hyperthermic isolated hepatic perfusion.
Over the years, a large number of drugs have been used in isolated perfusion of extremities or organs. To interpret the pharmacokinetics of these drugs correctly, the contributions of tissue or organ clearance and chemical degradation, respectively, to overall drug elimination from the circuit need to be identified. In support of a phase I clinical trial of isolated hepatic perfusion (IHP), delivering 5-fluorouracil (5-FU) and oxaliplatin to patients with colorectal cancer hepatic metastases, we aimed to characterize the stability of 5-FU and oxaliplatin in the IHP circuit. Stability of 5-FU and oxaliplatin was assessed in human blood, lactated Ringer infusion (LRI), and in an in vitro IHP circuit consisting of both blood and LRI. Samples were analyzed with liquid chromatography tandem mass spectrometry (5-FU) and atomic absorption spectrophotometry (oxaliplatin). 5-FU was stable under all tested in vitro conditions, but ultrafilterable platinum concentrations decreased slowly with a half-life of 85 minutes in both IHP perfusate and whole blood. The stability of 5-FU in the media containing blood is likely attributable to saturation of dihydropyrimidine dehydrogenase. The decrease of ultrafilterable platinum in blood-containing media with an 85 minutes half-life is in agreement with previous reports on oxaliplatin biotransformation. Oxaliplatin and 5-FU are sufficiently stable in the circuit for the 1-hour perfusion in ongoing and planned clinical trials.
Colville
Heidi
H
Shadyside Hospital Perfusion Services, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA.
Dzadony
Ryan
R
Kemp
Rebecca
R
Stewart
Stephen
S
Zeh
Herbert J
HJ
Bartlett
David L
DL
Holleran
Julianne
J
Schombert
Kevin
K
Kosovec
Juliann E
JE
Egorin
Merrill J
MJ
Beumer
Jan H
JH
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000737:chemistry*; D001774:Blood Chemical Analysis; D004355:Drug Stability; D005472:Fluorouracil / Q000737:chemistry*; D006801:Humans; D006979:Hyperthermia, Induced / Q000379:methods; D008099:Liver; D009944:Organoplatinum Compounds / Q000737:chemistry*; D000077150:Oxaliplatin; D010477:Perfusion / Q000379:methods
D009944:Organoplatinum Compounds; D000077150:Oxaliplatin; D005472:Fluorouracil